Compare CVS Health Corp (CVS) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Philip Morris International Inc. — how do they compare? CVS Health Corp trades at $106.03 (market cap $135.12B), while Philip Morris International Inc. trades at $176.88 (market cap $280.84B). The key difference: Philip Morris International Inc. is far larger — about 2.1× CVS Health Corp's market cap, and Philip Morris International Inc. pays the higher dividend (3.26%). Which is the better fit depends on your goals.
| CVS | PM | |
|---|---|---|
Market Cap | $135.12B | $280.84B |
Sector | Health | Consumer Staples |
52-Week High | $106.18 | $191.86 |
52-Week Low | $58.75 | $144.33 |
Enterprise Value | $201.66B | $327.33B |
Dividend Yield | 2.51% | 3.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $105.9, up 1.68% recently, with a bullish technical signal and strong analyst support (84.6% buy ratings). The company has beaten earnings estimates for three consecutive quarters, including Q1 2026 EPS of $2.57 versus $2.18 expected. Revenue growth remains robust, reaching $402.07B in 2025, though net margins are thin at 0.72%. Recent news highlights a settlement with the FTC advancing prescription drug affordability initiatives.
The outlook is positive given earnings momentum and strategic positioning in healthcare services, but risks include regulatory pressures and margin compression. The consensus price target of $110.62 suggests modest upside from current levels, supported by dividend payments and institutional confidence.
Philip Morris International (PM) trades at $175.95, down 3.12% on the day, amid a recent profit forecast revision. The stock shows a bullish technical signal with key support at $175 and resistance at $183. Fundamentally, the company reported strong 2025 results with $40.65B revenue and $11.35B net income, though a $500M impairment charge and cost pressures prompted a lowered 2026 outlook. Analyst sentiment remains positive with a $194 consensus price target and 68% buy ratings.
The outlook is cautiously optimistic; earnings growth and the IQOS brand strength offer upside, but regulatory risks and illicit market pressures pose challenges. The current price presents a potential entry point below the analyst target, though investors must weigh margin pressures from energy costs and currency swings noted in recent company guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
